Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1664336 | 0.84 | ESR1 (0.60) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1666112 | 0.82 | PDE10A (0.53) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1664551 | 0.81 | PDE10A (0.50) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1665671 | 0.77 | ALDH1A1 (0.49) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1663630 | 0.77 | ESR1 (0.57) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1664004 | 0.76 | ESR1 (0.84) | ESR1TRPV1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1663101 | 0.76 | ALDH1A1 (0.45) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1663648 | 0.74 | ESR1 (0.53) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL1663398 | 0.74 | TRPV1 (0.72) | ESR1TRPV1PDE10AALDH1A1ESR2 | |
| SCHEMBL10446406 | 0.74 | ESR1 (0.50) | ESR1TRPV1PDE10AESR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | ESR1 1321/4885TRPV1 1/4885PDE10A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.